Ovarian Serous Adenocarcinoma — Trials

Ovarian Serous Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

151 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 69
Recruiting: 29
Ph III recruiting: 4
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 42.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (20)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	Phase 2 / Phase 3	260	National Cancer Institute (NCI)NIH	2	Aug 4, 2026	clinicaltrials
NCT00951496	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	completed	Phase 3	1,560	National Cancer Institute (NCI)NIH	1	Jun 2, 2026